Shots:
- The US FDA has received a 510(k) premarket notification for Anchor Point Tracking, a tumor tracking technology designed for use with its new RefleXion X2 radiotherapy platform
- Filing is backed by extensive system validation & phantom testing, with additional data from academic investigators demonstrating improved target tracking, dose conformity, motion management, & organ-at-risk sparing to be presented at the AAPM 2026
- The platform quadruples PET detectors to significantly boost PET sensitivity, generating higher-fidelity biologic data for autonomous features like Anchor Point Tracking. The tech uses biologic PET “anchors” to improve treatment precision and, if cleared, expand SCINTIX therapy to more tumor sizes, shapes, & motion profiles
Ref: Businesswire | Image: RefleXion | Press Release
Related News: RefleXion Medical Reports the US FDA Clearance of RefleXion X2 Platform for Improved Tumor Detection
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
